Pfizer Inc. (NYSE: PFE) Q4 2020 earnings call dated Feb. 02, 2021
Corporate Participants:
Charles E. Triano — Senior Vice President, Investor Relations
Albert Bourla — Chairman and Chief Executive Officer
Mikael Dolsten — Chief Scientific Officer and President, Worldwide Research, Development and Medical
Angela Hwang — Group President, Pfizer Biopharmaceuticals Group
Frank D’Amelio — Chief Financial Officer and Executive Vice President, Global Supply
John Young — Group President, Chief Business Officer
Analysts:
David Risinger — Morgan Stanley — Analyst
Steve Scala — Cowen — Analyst
Gregg Gilbert — Truist Securities — Analyst
Louise Chen — Cantor Fitzgerald — Analyst
Umer Raffat — Evercore — Analyst
Geoffrey Porges — SVB Leerink — Analyst
Vamil Divan — Mizuho — Analyst
Tim Anderson — Wolfe Research — Analyst
Jason Zemansky — Bank of America — Analyst
Ronny Gal — Bernstein — Analyst
Navin Jacob — UBS — Analyst
Chris Schott — JPMorgan — Analyst
_________
To read the full earnings call transcript, click here
Most Popular
Infographic: Key metrics from Estee Lauder’s (EL) Q3 2024 earnings results
The Estee Lauder Companies Inc. (NYSE: EL) reported its third quarter 2024 earnings results today. Net sales were $3.94 billion, up 5% from the prior-year quarter. Organic sales increased 6%.
YUM Earnings: Key quarterly highlights from Yum! Brands’ Q1 2024 financial results
Yum! Brands, Inc. (NYSE: YUM) reported first quarter 2024 earnings results today. Total revenues decreased 3% year-over-year to $1.59 billion. Same-store sales declined 3%. Net income increased 5% to $314
Pfizer (PFE) Q1 2024 Earnings: Key financials and quarterly highlights
Pfizer Inc. (NYSE: PFE) reported first quarter 2024 earnings results today. Revenues decreased 20% year-over-year to $14.8 billion. Reported net income declined 44% to $3.1 billion, or $0.55 per share,